Evidence map›Paper›PMID 20587514›Full record

ArticleCancer research2010

Mouse models for the p53 R72P polymorphism mimic human phenotypes.

Feng Zhu, Martijn E T Dollé, Thomas R Berton, Raoul V Kuiper, Carrie Capps, Alexsandra Espejo, Mark J McArthur, Mark T Bedford, Harry van Steeg, Annemieke de Vries and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. IntronicCancers · 2020
    Article
  7. Article
  8. Modulating native GABAJournal of neuro-oncology · 2019
    Article
  9. Article
  10. Control of metabolism by p53 - Cancer and beyond.Biochimica et biophysica acta. Reviews on cancer · 2018
    Review
  11. Article
  12. TP53 p.R72P genotype is a marker of poor prognosis in lung cancer.Cancer biomarkers : section A of Disease markers · 2018
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Association of TP53 gene polymorphisms with susceptibility of bladder cancer in Bangladeshi population.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Feng ZhuDepartment of Carcinogenesis, Science Park-Research Division, The University of Texas MD Anderson Cancer Center, Smithville, Texas 78957, USA.
Martijn E T Dollé
Thomas R Berton
Raoul V Kuiper
Carrie Capps
Alexsandra Espejo
Mark J McArthur
Mark T Bedford
Harry van Steeg
Annemieke de Vries
David G Johnson
The University of Texas MD Anderson Cancer Center · USUtrecht University · NLNational Institute for Public Health and the Environment · NLUniversity of Houston · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MYERS, JEFFREY NICHOLAS · 2002 to 2012
$26.1M
Pilot Project ProgramP30ES007784 · NIEHS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI RICHIE, ELLEN R · 1996 to 2011
$16.4M
Mouse Model of Cell Cycle Deregulation in CancerU01ES011047 · NIEHS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI JOHNSON, DAVID G. · 2001 to 2006
$6.8M
Models for DNA repair and cell cycle control variantsU01ES011044 · NIEHS · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI VIJG, JAN · 2001 to 2006
$5.1M
RESEARCH TRAINING IN CARCINOGENESIS &MUTAGENESIST32CA009480 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI RICHIE, ELLEN R · 1985 to 2012
$3.0M
Humanized Mouse Models for the p53 R72P SNPR01ES015587 · NIEHS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI JOHNSON, DAVID G. · 2009 to 2013
$2.2M
NCI NIH HHS CA009480NCI NIH HHS CA016672NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA097007NCI NIH HHS P50CA097007NCI NIH HHS T32 CA009480NIEHS NIH HHS ES015587NIEHS NIH HHS P30 ES007784NIEHS NIH HHS P30ES007784NIEHS NIH HHS R01 ES015587NIEHS NIH HHS U01 ES011044NIEHS NIH HHS U01 ES011047NIEHS NIH HHS U01 ES11044
6 · The paper itself

Abstract

The p53 tumor suppressor gene contains a common single nucleotide polymorphism (SNP) that results in either an arginine or proline at position 72 of the p53 protein. This polymorphism affects the apoptotic activity of p53 but the mechanistic basis and physiologic relevance of this phenotypic difference remain unclear. Here, we describe the development of mouse models for the p53 R72P SNP using two different approaches. In both sets of models, the human or humanized p53 proteins are functional as evidenced by the transcriptional induction of p53 target genes in response to DNA damage and the suppression of early lymphomagenesis. Consistent with in vitro studies, mice expressing the 72R variant protein (p53R) have a greater apoptotic response to several stimuli compared with mice expressing the p53P variant. Molecular studies suggest that both transcriptional and nontranscriptional mechanisms may contribute to the differential abilities of the p53 variants to induce apoptosis. Despite a difference in the acute response to UV radiation, no difference in the tumorigenic response to chronic UV exposure was observed between the polymorphic mouse models. These findings suggest that under at least some conditions, the modulation of apoptosis by the R72P polymorphism does not affect the process of carcinogenesis.

Indexed as

AnimalsApoptosisChromosomes, Artificial, BacterialCodonExonsHumansMiceMice, TransgenicMitochondriaModels, AnimalOncogene Proteins, FusionPhenotypePolymorphism, Single NucleotideSkin NeoplasmsTranscription, GeneticTumor Suppressor Protein p53CodonOncogene Proteins, FusionTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID20587514
PMCPMC2905499
OpenAlexW2158076001

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.